Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P.

JAMA. 2008 Nov 5;300(17):2003-11. doi: 10.1001/jama.2008.574. Erratum in: JAMA. 2009 Feb 25;301(8):830. JAMA. 2013 Apr 10;309(14):1461.

PMID:
18984887
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.

Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, Trivedi M, Weiss R, Potter J, Poole SA, Woody GE.

J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1120-8. doi: 10.1016/j.jaac.2011.07.010.

PMID:
22024000
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE.

Addiction. 2010 Sep;105(9):1616-24. doi: 10.1111/j.1360-0443.2010.03001.x. Epub 2010 Jul 12.

PMID:
20626379
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

PMID:
22065255
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL.

JAMA. 2010 Oct 13;304(14):1576-83. doi: 10.1001/jama.2010.1427.

PMID:
20940383
[PubMed - indexed for MEDLINE]
6.

Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants.

Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G.

Addict Behav. 2013 Oct;38(10):2568-74. doi: 10.1016/j.addbeh.2013.05.015. Epub 2013 Jun 13.

PMID:
23811060
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL.

Addiction. 2013 Dec;108(12):2141-9. doi: 10.1111/add.12315. Epub 2013 Sep 18.

PMID:
23919595
[PubMed - indexed for MEDLINE]
8.

A trial of integrated buprenorphine/naloxone and HIV clinical care.

Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S184-90.

PMID:
17109305
[PubMed - indexed for MEDLINE]
Free Article
9.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
[PubMed - indexed for MEDLINE]
10.

Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.

Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, Potter J, Fishman M, Bogenschutz M, Patkar A, Trivedi MH.

Addict Behav. 2012 Sep;37(9):1046-53. doi: 10.1016/j.addbeh.2012.04.011. Epub 2012 May 8.

PMID:
22626890
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS.

N Engl J Med. 2006 Jul 27;355(4):365-74.

PMID:
16870915
[PubMed - indexed for MEDLINE]
Free Article
12.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
[PubMed - indexed for MEDLINE]
13.

Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?

Caldiero RM, Parran TV Jr, Adelman CL, Piche B.

Am J Addict. 2006 Jan-Feb;15(1):1-7.

PMID:
16449087
[PubMed - indexed for MEDLINE]
14.

Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Amato P.

Clin Drug Investig. 2010;30 Suppl 1:33-9. doi: 10.2165/11536060-000000000-00000.

PMID:
20450244
[PubMed - indexed for MEDLINE]
15.

A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn JR, Higgins ST.

JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 10.1001/jamapsychiatry.2013.2216.

PMID:
24153411
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.

Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE.

J Subst Abuse Treat. 2012 Dec;43(4):433-9. doi: 10.1016/j.jsat.2012.07.011. Epub 2012 Aug 29.

PMID:
22938914
[PubMed - indexed for MEDLINE]
17.

The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.

Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA.

Am J Addict. 2010 Jan-Feb;19(1):53-8. doi: 10.1111/j.1521-0391.2009.00003.x.

PMID:
20132122
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Buprenorphine tapering schedule and illicit opioid use.

Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R.

Addiction. 2009 Feb;104(2):256-65. doi: 10.1111/j.1360-0443.2008.02455.x.

PMID:
19149822
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Primary Care-Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG.

JAMA Intern Med. 2014 Dec 1;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.

PMID:
25330017
[PubMed - in process]
20.

Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.

Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD.

Drug Alcohol Depend. 2010 Mar 1;107(2-3):253-6. doi: 10.1016/j.drugalcdep.2009.10.014. Epub 2009 Nov 30.

PMID:
19948382
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk